Targeting Nuclear Acid-mediated Immunity in Cancer Immune Checkpoint Inhibitor Therapies

Overview

Journal Signal Transduct Target Ther

Specialties Cell Biology
Pharmacology

Date 2020 Nov 20

PMID 33214545

Citations 20

Authors

Miaoqin Chen

Shiman Hu

Yiling Li

Ting Ting Jiang

Hongchuan Jin

Lifeng Feng

Affiliations

Soon will be listed here.

Abstract

Cancer immunotherapy especially immune checkpoint inhibition has achieved unprecedented successes in cancer treatment. However, there are many patients who failed to benefit from these therapies, highlighting the need for new combinations to increase the clinical efficacy of immune checkpoint inhibitors. In this review, we summarized the latest discoveries on the combination of nucleic acid-sensing immunity and immune checkpoint inhibitors in cancer immunotherapy. Given the critical role of nuclear acid-mediated immunity in maintaining the activation of T cell function, it seems that harnessing the nuclear acid-mediated immunity opens up new strategies to enhance the effect of immune checkpoint inhibitors for tumor control.

Citing Articles

Nucleic acid sensing in the central nervous system: Implications for neural circuit development, function, and degeneration.

Stillman J, Kiniwa T, Schafer D Immunol Rev. 2024; 327(1):71-82.

PMID: 39503567 PMC: 11653434. DOI: 10.1111/imr.13420.

Unleashing viral mimicry: A combinatorial strategy to enhance the efficacy of PARP7 inhibitors.

Manetsch P, Hottiger M Bioessays. 2024; 47(2):e2400087.

PMID: 39502005 PMC: 11755700. DOI: 10.1002/bies.202400087.

Perforin 1 in Cancer: Mechanisms, Therapy, and Outlook.

Guan X, Guo H, Guo Y, Han Q, Li Z, Zhang C Biomolecules. 2024; 14(8).

PMID: 39199299 PMC: 11352983. DOI: 10.3390/biom14080910.

RNA mC methylation: a potential modulator of innate immune pathways in hepatocellular carcinoma.

Meng S, Jiangtao B, Haisong W, Mei L, Long Z, Shanfeng L Front Immunol. 2024; 15:1362159.

PMID: 38807595 PMC: 11131105. DOI: 10.3389/fimmu.2024.1362159.

Cigarette smoke sustains immunosuppressive microenvironment inducing M2 macrophage polarization and viability in lung cancer settings.

Bianchi F, Le Noci V, Bernardo G, Gagliano N, Colombo G, Sommariva M PLoS One. 2024; 19(5):e0303875.

PMID: 38776331 PMC: 11111031. DOI: 10.1371/journal.pone.0303875.

References

Ghaffari A, Peterson N, Khalaj K, Vitkin N, Robinson A, Francis J . STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer. Br J Cancer. 2018; 119(4):440-449. PMC: 6133940. DOI: 10.1038/s41416-018-0188-5. View

Block M, Nevala W, Pang Y, Allred J, Strand C, Markovic S . A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1. Melanoma Res. 2018; 29(4):420-427. DOI: 10.1097/CMR.0000000000000556. View

Qin Y, Vasilatos S, Chen L, Wu H, Cao Z, Fu Y . Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene. 2018; 38(3):390-405. PMC: 6336685. DOI: 10.1038/s41388-018-0451-5. View

Ager C, Reilley M, Nicholas C, Bartkowiak T, Jaiswal A, Curran M . Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity. Cancer Immunol Res. 2017; 5(8):676-684. PMC: 5547907. DOI: 10.1158/2326-6066.CIR-17-0049. View

Savarese E, Chae O, Trowitzsch S, Weber G, Kastner B, Akira S . U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood. 2005; 107(8):3229-34. DOI: 10.1182/blood-2005-07-2650. View

Spranger S, Dai D, Horton B, Gajewski T . Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017; 31(5):711-723.e4. PMC: 5650691. DOI: 10.1016/j.ccell.2017.04.003. View

Sheng W, LaFleur M, Nguyen T, Chen S, Chakravarthy A, Conway J . LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. Cell. 2018; 174(3):549-563.e19. PMC: 6063761. DOI: 10.1016/j.cell.2018.05.052. View

Fu J, Kanne D, Leong M, Glickman L, McWhirter S, Lemmens E . STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med. 2015; 7(283):283ra52. PMC: 4504692. DOI: 10.1126/scitranslmed.aaa4306. View

Corrales L, Glickman L, McWhirter S, Kanne D, Sivick K, Katibah G . Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015; 11(7):1018-30. PMC: 4440852. DOI: 10.1016/j.celrep.2015.04.031. View

10.

Takeda K, Tsutsui H, Yoshimoto T, Adachi O, Yoshida N, Kishimoto T . Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity. 1998; 8(3):383-90. DOI: 10.1016/s1074-7613(00)80543-9. View

11.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

12.

Muro K, Chung H, Shankaran V, Geva R, Catenacci D, Gupta S . Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016; 17(6):717-726. DOI: 10.1016/S1470-2045(16)00175-3. View

13.

Dai P, Wang W, Yang N, Serna-Tamayo C, Ricca J, Zamarin D . Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. Sci Immunol. 2017; 2(11). PMC: 5559204. DOI: 10.1126/sciimmunol.aal1713. View

14.

Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak J, Eguchi J . Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med. 2007; 5:10. PMC: 1802742. DOI: 10.1186/1479-5876-5-10. View

15.

Barry K, Hsu J, Broz M, Cueto F, Binnewies M, Combes A . A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018; 24(8):1178-1191. PMC: 6475503. DOI: 10.1038/s41591-018-0085-8. View

16.

Venkataraman T, Valdes M, Elsby R, Kakuta S, Caceres G, Saijo S . Loss of DExD/H box RNA helicase LGP2 manifests disparate antiviral responses. J Immunol. 2007; 178(10):6444-55. DOI: 10.4049/jimmunol.178.10.6444. View

17.

Unterholzner L, Keating S, Baran M, Horan K, Jensen S, Sharma S . IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol. 2010; 11(11):997-1004. PMC: 3142795. DOI: 10.1038/ni.1932. View

18.

. Warming "Cold" Melanoma with TLR9 Agonists. Cancer Discov. 2018; 8(6):670. DOI: 10.1158/2159-8290.CD-ND2018-004. View

19.

Lu H, Dietsch G, Matthews M, Yang Y, Ghanekar S, Inokuma M . VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res. 2011; 18(2):499-509. DOI: 10.1158/1078-0432.CCR-11-1625. View

20.

Joseph R, Cappel M, Tzou K, Bagaria S, Gilstrap C, Swaika A . Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod. Melanoma Res. 2016; 26(4):409-12. DOI: 10.1097/CMR.0000000000000247. View